查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602773

僵直性脊椎炎市場：按藥物、分子類型、作用機制、給藥途徑、劑型和最終用戶分類 - 2025-2030 年全球預測

Ankylosing Spondylitis Market by Drug (Cimzia, Cosentyx, Enbrel), Type of Molecule (Biologics, Small Molecules), Mechanism Of Action, Route Of Administration, Dosage Forms, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

僵直性脊椎炎市場2023年估值為51.8億美元，預計2024年將達56億美元，複合年成長率為8.31%，到2030年將達到90.6億美元。

僵直性脊椎炎(AS) 是一種慢性發炎疾病，主要影響脊椎和大關節，導致嚴重疼痛和潛在的殘疾。 AS 治療市場包括生技藥品、生物相似藥和小分子，重點在於提高藥物療效和安全性。 AS 盛行率不斷上升，尤其是在 20 歲至 40 歲之間的年輕人中，並且需要針對個人遺傳和生活方式因素進行客製化治療，這推動了對 AS 治療的需求。這些治療的應用正在擴展到醫院、零售藥局、線上藥局以及強調以患者為中心的護理的醫療保健系統的最終用途。關鍵的成長要素包括意識的提高、診斷技術的改進以及創新治療管道的擴大。生技藥品，特別是 TNF 抑制劑和 IL-17 抑制劑，由於其在控制症狀方面的有效性而對市場成長產生重大影響。然而，高昂的治療費用、專利到期和AS的慢性化已成為主要問題。新的治療機會在於生物相似藥和JAK抑制劑的探索，這可能提供具有成本效益的替代方案和新的治療途徑。隨著付款人和政策制定者越來越關注基於以金額為準的定價，相關人員掌握報銷格局至關重要。面臨的挑戰是疾病的早期發現，現有治療方法的副作用和通常的特異性症狀阻礙了疾病的早期發現。創新領域包括用於早期診斷的生物標記研究和個人化醫療方法，其中基因治療和先進生技藥品的前景引起了人們的關注。 AS 市場本質上是競爭性的，需要生物技術公司、研究機構和監管機構之間持續的研發投資和合作，以維持強大的產品線。透過利用真實世界的證據和患者資料分析，公司可以增強其藥物開發策略並有效解決未滿足的臨床需求。

主要市場統計
基準年[2023] 51.8億美元
預測年份 [2024] 56億美元
預測年份 [2030] 90.6億美元
複合年成長率（%） 8.31%

市場動態：揭示快速發展的僵直性脊椎炎市場的關鍵市場洞察

僵直性脊椎炎市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 僵直性脊椎炎增加
    • 提高疾病診斷和治療意識
    • 整形外科醫院和診斷中心的增加
  • 市場限制因素
    • 治療費用上漲，熟練的外科醫生和物理治療師短缺
  • 市場機會
    • 加速脊椎炎治療的研發成本
    • 治療僵直性脊椎炎的生技藥品的出現
  • 市場問題
    • 對認證核可藥專利到期的擔憂

波特五力：駕馭僵直性脊椎炎市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解僵直性脊椎炎市場的外部影響

外部宏觀環境因素在塑造僵直性脊椎炎市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解僵直性脊椎炎市場的競爭格局

僵直性脊椎炎市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：僵直性脊椎炎市場供應商的績效評估

FPNV 定位矩陣是評估僵直性脊椎炎市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製僵直性脊椎炎市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，僵直性脊椎炎市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 僵直性脊椎炎的發生率增加
      • 提高疾病診斷和治療意識
      • 整形外科醫院和診斷中心的增加
    • 抑制因素
      • 治療成本上升，熟練的外科醫生和物理治療師短缺
    • 機會
      • 加速脊椎炎治療的研發支出
      • 治療僵直性脊椎炎的生技藥品的出現
    • 任務
      • 對已核准藥物專利到期的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章僵直性脊椎炎市場：依藥物分類

  • 介紹
  • Cimzia
  • 科森泰克斯
  • Enbrel
  • Humira
  • Remicade
  • 辛波尼

第7章僵直性脊椎炎市場：依分子類型

  • 介紹
  • 生技藥品
  • 小分子

第8章僵直性脊椎炎市場：按作用機制

  • 介紹
  • Cyclooxygenase抑制劑
  • 腫瘤壞死因子抑制劑

第9章僵直性脊椎炎市場：依給藥途徑

  • 介紹
  • 口服
  • 胃腸外的

第10章僵直性脊椎炎炎市場：按劑型

  • 介紹
  • 液體
  • 固體的

第11章僵直性脊椎炎市場：依最終用戶分類

  • 介紹
  • 診所
  • 醫院

第12章北美和南美僵直性脊椎炎市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太僵直性脊椎炎市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲僵直性脊椎炎市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • BIoThera Pharmaceuticals, Inc. by HiberCell, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Celltrion Healthcare Co.,Ltd.
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • Hetero Drugs Limited
  • Novartis AG
  • Reliance Life Sciences
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Sanofi-Aventis Groupe SA
  • Shanghai Pharmaceuticals Holding Co., Ltd.
  • Trinity BIoTech PLC
  • Xian Janssen Pharmaceutical Ltd
Product Code: MRR-A339DAEFAA9A

The Ankylosing Spondylitis Market was valued at USD 5.18 billion in 2023, expected to reach USD 5.60 billion in 2024, and is projected to grow at a CAGR of 8.31%, to USD 9.06 billion by 2030.

Ankylosing Spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine and large joints, leading to severe pain and potential disability. The market for AS treatments encompasses biologics, biosimilars, and small molecules, with a focus on advancements in drug efficacy and safety. The necessity for AS treatments is driven by the increasing prevalence of the disease, particularly among young adults aged 20-40, and the need for tailored therapeutics that address individual genetic and lifestyle factors. Application of these therapies extends across hospitals, retail pharmacies, and online pharmacies, with end-use scope expanding to health systems emphasizing patient-centered care. Key growth factors include heightened awareness, improved diagnostic technologies, and an expanding pipeline of innovative therapeutics. Biologics, particularly TNF inhibitors and IL-17 inhibitors, have substantially influenced market growth due to their effectiveness in managing symptoms. However, high treatment costs, patent expirations, and the chronicity of AS pose significant challenges. Emerging opportunities lie in biosimilars and the exploration of JAK inhibitors, which offer potential cost-effective alternatives and novel pathways to treatment. Payers and policymakers increasingly focus on value-based pricing, making it crucial for stakeholders to navigate reimbursement landscapes adeptly. Limitations include the side effects of existing therapies and the challenge of early disease detection, often impeded by non-specific symptoms. Innovation areas encompass biomarker research for early diagnosis and personalized medicine approaches, spotlighting the promise of gene therapy and advanced biologics. The AS market is inherently competitive, demanding relentless R&D investment and collaborations between biotech firms, research institutions, and regulatory bodies to maintain a robust pipeline. By leveraging real-world evidence and patient data analytics, companies can enhance drug development strategies and address unmet clinical needs effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 5.18 billion
Estimated Year [2024] USD 5.60 billion
Forecast Year [2030] USD 9.06 billion
CAGR (%) 8.31%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ankylosing Spondylitis Market

The Ankylosing Spondylitis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of ankylosing spondylitis
    • Growing awareness about diagnostics and treatments for the disease
    • Rising number of orthopedic hospitals and diagnostic centers
  • Market Restraints
    • High cost of treatment and dearth of skilled surgeons and physiotherapists
  • Market Opportunities
    • Acceleration in research and development expenditure for the treatment of the spondylitis
    • The emergence of biologics for treating ankylosing spondylitis
  • Market Challenges
    • Concerns related to patent expiration of already approved drugs

Porter's Five Forces: A Strategic Tool for Navigating the Ankylosing Spondylitis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ankylosing Spondylitis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ankylosing Spondylitis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ankylosing Spondylitis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ankylosing Spondylitis Market

A detailed market share analysis in the Ankylosing Spondylitis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ankylosing Spondylitis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ankylosing Spondylitis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ankylosing Spondylitis Market

A strategic analysis of the Ankylosing Spondylitis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ankylosing Spondylitis Market, highlighting leading vendors and their innovative profiles. These include Biothera Pharmaceuticals, Inc. by HiberCell, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Celltrion Healthcare Co.,Ltd., Eisai Co., Ltd, Eli Lilly and Company, Hetero Drugs Limited, Novartis AG, Reliance Life Sciences, Samsung Bioepis Co., Ltd., Sandoz International GmbH, Sanofi-Aventis Groupe S.A., Shanghai Pharmaceuticals Holding Co., Ltd., Trinity Biotech PLC, and Xian Janssen Pharmaceutical Ltd.

Market Segmentation & Coverage

This research report categorizes the Ankylosing Spondylitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Cimzia, Cosentyx, Enbrel, Humira, Remicade, and Simponi.
  • Based on Type of Molecule, market is studied across Biologics and Small Molecules.
  • Based on Mechanism Of Action, market is studied across Cyclooxygenase Inhibitors and Tumor Necrosis Factor Inhibitors.
  • Based on Route Of Administration, market is studied across Oral and Parenteral.
  • Based on Dosage Forms, market is studied across Liquid and Solid.
  • Based on End User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of ankylosing spondylitis
      • 5.1.1.2. Growing awareness about diagnostics and treatments for the disease
      • 5.1.1.3. Rising number of orthopedic hospitals and diagnostic centers
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and dearth of skilled surgeons and physiotherapists
    • 5.1.3. Opportunities
      • 5.1.3.1. Acceleration in research and development expenditure for the treatment of the spondylitis
      • 5.1.3.2. The emergence of biologics for treating ankylosing spondylitis
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns related to patent expiration of already approved drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Ankylosing Spondylitis Market, by Drug

  • 6.1. Introduction
  • 6.2. Cimzia
  • 6.3. Cosentyx
  • 6.4. Enbrel
  • 6.5. Humira
  • 6.6. Remicade
  • 6.7. Simponi

7. Ankylosing Spondylitis Market, by Type of Molecule

  • 7.1. Introduction
  • 7.2. Biologics
  • 7.3. Small Molecules

8. Ankylosing Spondylitis Market, by Mechanism Of Action

  • 8.1. Introduction
  • 8.2. Cyclooxygenase Inhibitors
  • 8.3. Tumor Necrosis Factor Inhibitors

9. Ankylosing Spondylitis Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parenteral

10. Ankylosing Spondylitis Market, by Dosage Forms

  • 10.1. Introduction
  • 10.2. Liquid
  • 10.3. Solid

11. Ankylosing Spondylitis Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Hospitals

12. Americas Ankylosing Spondylitis Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Ankylosing Spondylitis Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Ankylosing Spondylitis Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Biothera Pharmaceuticals, Inc. by HiberCell, Inc.
  • 2. Boehringer Ingelheim International GmbH
  • 3. Bristol-Myers Squibb
  • 4. Celltrion Healthcare Co.,Ltd.
  • 5. Eisai Co., Ltd
  • 6. Eli Lilly and Company
  • 7. Hetero Drugs Limited
  • 8. Novartis AG
  • 9. Reliance Life Sciences
  • 10. Samsung Bioepis Co., Ltd.
  • 11. Sandoz International GmbH
  • 12. Sanofi-Aventis Groupe S.A.
  • 13. Shanghai Pharmaceuticals Holding Co., Ltd.
  • 14. Trinity Biotech PLC
  • 15. Xian Janssen Pharmaceutical Ltd

LIST OF FIGURES

  • FIGURE 1. ANKYLOSING SPONDYLITIS MARKET RESEARCH PROCESS
  • FIGURE 2. ANKYLOSING SPONDYLITIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANKYLOSING SPONDYLITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANKYLOSING SPONDYLITIS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CIMZIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COSENTYX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ENBREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HUMIRA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REMICADE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SIMPONI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 279. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 280. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2023